(Sharecast News) - London stocks closed higher on Friday as investors digested a slowdown in the Federal Reserve's preferred inflation measure. The FTSE 100 gained 0.43% to reach 8,320.76, while the ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) has achieved a significant milestone with the FDA's recent approval of Cobenfy ...

Bristol-Myers Squibb (BMY) shares rose early Friday as the biopharmaceutical company obtained approval from the US Food and Drug Administration for its Cobenfy drug to treat schizophrenia in adults.

London stocks had extended gains by midday on Friday as Chinese markets enjoyed their best week since 2008 on the back of ...

PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone ...

Christine Lagarde is under pressure to ramp up the pace of interest rate cuts in the eurozone after French and Spanish ...

In company news, PureTech Health reported US Food & Drug Administration approval for its schizophrenia drug, and abrdn Property Income Trust agreed to sell a subsidiary for GBP351 million. Here is ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

London open The FTSE 100 is expected to open eight points higher on Friday, having closed up 0.2% on Thursday at 8,284.91.

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

Industry leaders came together at the e4m IDAC Summit 2024 to discuss the shifts in the marketing landscape and the ...

Andrew Miller, then an executive at PureTech Health, licensed xanomeline in 2012 and founded Karuna to develop the treatment. Karuna solved the side effect problem by adding trospium, a muscarinic ...